share_log

中國中藥：根據《收購守則》規則22作出的交易披露

TRAD CHI MED: Disclosure of Dealings under Rule 22 of the Takeovers Code

香港交易所 ·  Feb 27 03:31
Summary by Moomoo AI
根據香港《公司收購及合併守則》規則22，中国中药控股有限公司於2024年2月27日披露了一宗股份交易。該交易涉及公司與第三類別聯繫人柳珊透過協議安排進行的私有化過程。柳珊於2024年2月26日賣出了200,000股中国中药股份，每股價格為4.32港元，交易後柳珊持股數量降至0股，佔公司同類別證券百分比為0.0000%。
根據香港《公司收購及合併守則》規則22，中国中药控股有限公司於2024年2月27日披露了一宗股份交易。該交易涉及公司與第三類別聯繫人柳珊透過協議安排進行的私有化過程。柳珊於2024年2月26日賣出了200,000股中国中药股份，每股價格為4.32港元，交易後柳珊持股數量降至0股，佔公司同類別證券百分比為0.0000%。
Pursuant to Rule 22 of the Hong Kong Code of Acquisitions and Mergers, China Pharmaceutical Holdings Limited disclosed a share transaction on 27 February 2024. The transaction involves the company's privatization process with Liushan, a third class contact, through a contractual arrangement. On February 26, 2024, Liu Shan sold 200,000 shares of PRC shares at HK$4.32 per share. After the transaction, the number of Liushan shares decreased to 0 shares, representing 0.0000% of the company's similar securities.
Pursuant to Rule 22 of the Hong Kong Code of Acquisitions and Mergers, China Pharmaceutical Holdings Limited disclosed a share transaction on 27 February 2024. The transaction involves the company's privatization process with Liushan, a third class contact, through a contractual arrangement. On February 26, 2024, Liu Shan sold 200,000 shares of PRC shares at HK$4.32 per share. After the transaction, the number of Liushan shares decreased to 0 shares, representing 0.0000% of the company's similar securities.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more